BR112016001522B1 - Composições de anticorpo estabilizado - Google Patents
Composições de anticorpo estabilizado Download PDFInfo
- Publication number
- BR112016001522B1 BR112016001522B1 BR112016001522-3A BR112016001522A BR112016001522B1 BR 112016001522 B1 BR112016001522 B1 BR 112016001522B1 BR 112016001522 A BR112016001522 A BR 112016001522A BR 112016001522 B1 BR112016001522 B1 BR 112016001522B1
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- antigen binding
- polypeptide
- binding protein
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13177699 | 2013-07-23 | ||
| EP13177699.9 | 2013-07-23 | ||
| PCT/EP2014/065840 WO2015011199A1 (en) | 2013-07-23 | 2014-07-23 | Stabilized antibody compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016001522B1 true BR112016001522B1 (pt) | 2019-10-01 |
Family
ID=48803483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016001522-3A BR112016001522B1 (pt) | 2013-07-23 | 2014-07-23 | Composições de anticorpo estabilizado |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10273298B2 (enExample) |
| EP (1) | EP3024484B1 (enExample) |
| JP (1) | JP6503349B2 (enExample) |
| KR (1) | KR102272568B1 (enExample) |
| CN (2) | CN105555311B (enExample) |
| AU (1) | AU2014295052B2 (enExample) |
| BR (1) | BR112016001522B1 (enExample) |
| CA (1) | CA2918419C (enExample) |
| DK (1) | DK3024484T3 (enExample) |
| ES (1) | ES2687094T3 (enExample) |
| MX (1) | MX370207B (enExample) |
| PL (1) | PL3024484T3 (enExample) |
| PT (1) | PT3024484T (enExample) |
| WO (1) | WO2015011199A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| JP6039145B2 (ja) | 2011-05-25 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ化アルカンを基礎にした局所薬学的組成物 |
| PT2806886T (pt) | 2012-01-23 | 2017-03-24 | Novaliq Gmbh | Composições de proteínas estabilizadas baseadas em alcanos semifluorados |
| MX363182B (es) | 2012-09-12 | 2019-03-13 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| EP2895144B1 (en) | 2012-09-12 | 2017-01-11 | Novaliq GmbH | Semifluorinated alkane compositions |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
| EP2893939A1 (en) * | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
| AR103726A1 (es) * | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
| US20170087100A1 (en) | 2015-09-30 | 2017-03-30 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| EP3722274B1 (en) | 2015-09-30 | 2023-06-07 | Novaliq GmbH | 2-perfluorobutyl pentane for ophthalmic administration |
| DK3442480T3 (da) | 2016-06-23 | 2020-01-13 | Novaliq Gmbh | Fremgangsmåde til topisk indgivelse |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| AU2017329983B2 (en) | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| MX381639B (es) | 2016-12-23 | 2025-03-13 | Novaliq Gmbh | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| JP7814839B2 (ja) | 2017-09-27 | 2026-02-17 | ノバリック ゲーエムベーハー | 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| AU2019246035B2 (en) | 2018-03-28 | 2024-07-18 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| JP7855312B2 (ja) | 2018-04-27 | 2026-05-08 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| US11510855B2 (en) | 2018-09-27 | 2022-11-29 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
| WO2020064549A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| MX2021004356A (es) | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
| MA54089A (fr) | 2018-10-31 | 2022-02-09 | Merck Sharp & Dohme | Anticorps anti-pd-1 humain et procédés d'utilisation associés |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤 |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| CN114449999A (zh) | 2019-09-06 | 2022-05-06 | 诺瓦利克有限责任公司 | 用于治疗葡萄膜炎的眼用组合物 |
| EP4065082A1 (en) * | 2019-11-27 | 2022-10-05 | Novaliq GmbH | Suspension comprising a protein particle suspended in a non-aqueous vehicle |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN115518038A (zh) * | 2021-06-25 | 2022-12-27 | 成都康弘药业集团股份有限公司 | 一种稳定的眼用制剂 |
| WO2025133214A1 (en) | 2023-12-21 | 2025-06-26 | Novaliq Gmbh | Ophthalmic polypeptide compositions for the treatment of posterior eye disorders |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
| US4452818A (en) | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
| US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
| EP0270056A1 (en) * | 1986-12-01 | 1988-06-08 | Northwestern University | Human LDH-C 4cDNA sequences encoding antigenic regions |
| JPS6452722A (en) | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
| US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
| US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
| US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
| US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
| DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
| FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
| FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
| IN184589B (enExample) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
| US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| CA2278328C (en) | 1998-02-09 | 2008-07-22 | Macrochem Corporation | Antifungal nail lacquer and method using same |
| DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| CN1221249C (zh) | 1998-08-19 | 2005-10-05 | 斯凯伊药品加拿大公司 | 普鲁泊福的可注射水分散体 |
| US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
| US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| EP1152749B1 (en) | 1999-02-08 | 2006-04-12 | ALZA Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| WO2000054588A1 (en) | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
| DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
| US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| WO2002089849A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
| US20040265362A1 (en) | 2001-09-04 | 2004-12-30 | Rudy Susilo | Plaster for the treatment of dysfunctions and disorders of nail growth |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| EP1663148A2 (en) | 2003-08-25 | 2006-06-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
| US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
| CA2540621A1 (en) | 2003-11-19 | 2005-06-09 | Barnes-Jewish Hospital | Enhanced drug delivery |
| GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| US20080019926A1 (en) | 2004-04-19 | 2008-01-24 | Marie-Pierre Krafft | Lung Surfactant Supplements |
| EP1763336A1 (en) | 2004-06-08 | 2007-03-21 | Ocularis Pharma, Inc. | Hydrophobic ophthalmic compositions and methods of use |
| AU2005262392A1 (en) | 2004-07-01 | 2006-01-19 | Johnson & Johnson Vision Care, Inc. | Compositions and methods for treating eye disorders and conditions |
| US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| GB0511499D0 (en) | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
| BRPI0614084A2 (pt) | 2005-08-05 | 2011-03-09 | Bharat Serums And Vaccines Limited | composição estável de emulsão de óleo-em-água de propofol, administrável por via intranovesa; e processo de preparação de uma composição |
| DE102005055811A1 (de) | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US20080089923A1 (en) | 2006-09-29 | 2008-04-17 | Burkstrand Michael J | Biodegradable ocular implants and methods for treating ocular conditions |
| US9000048B2 (en) | 2006-11-28 | 2015-04-07 | Wisconsin Alumni Research Foundation | Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics |
| DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
| PL2110126T3 (pl) * | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
| US20100000899A1 (en) * | 2008-07-07 | 2010-01-07 | Panasonic Corporation | Medication blister pack with embedded user interface |
| JP2012509737A (ja) | 2008-11-26 | 2012-04-26 | サーモディクス，インコーポレイティド | 埋め込み式の眼薬送達器具および眼薬送達方法 |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
| WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
| JP5549669B2 (ja) | 2009-06-25 | 2014-07-16 | ライオン株式会社 | 眼科用組成物、ドライアイ治療剤及びビタミンａの安定化方法 |
| JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
| PT2387391T (pt) | 2009-07-24 | 2017-04-20 | Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh | Processo para o desenvolvimento de uma composição líquida a ser aplicada na forma de espuma sobre a pele e composição de aplicação tópica |
| EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| WO2011112669A1 (en) * | 2010-03-09 | 2011-09-15 | Centocor Ortho Biotech Inc. | Non-aqueous high concentration reduced viscosity suspension formulations |
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| DE102010022567A1 (de) | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| EP2661280B1 (en) | 2011-01-04 | 2018-11-21 | Novaliq GmbH | O/w-emulsions comprising semifluorinated alkanes |
| WO2012142670A1 (en) * | 2011-04-20 | 2012-10-26 | The University Of Queensland | Nuclear magnetic resonance agent |
| CN103561724B (zh) | 2011-05-25 | 2016-06-29 | 诺瓦利克有限责任公司 | 给药给甲的药物组合物 |
| JP6039145B2 (ja) | 2011-05-25 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ化アルカンを基礎にした局所薬学的組成物 |
| PT2806886T (pt) * | 2012-01-23 | 2017-03-24 | Novaliq Gmbh | Composições de proteínas estabilizadas baseadas em alcanos semifluorados |
| SI2849723T1 (sl) | 2012-05-18 | 2018-09-28 | Genentech, Inc. | Formulacije z visoko koncentracijo monoklonskih protiteles |
| MX363182B (es) | 2012-09-12 | 2019-03-13 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| EP2895144B1 (en) | 2012-09-12 | 2017-01-11 | Novaliq GmbH | Semifluorinated alkane compositions |
| KR20150095684A (ko) | 2012-12-18 | 2015-08-21 | 노파르티스 아게 | 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법 |
| EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
| DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
| EP2944324A1 (de) | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| EP3722274B1 (en) | 2015-09-30 | 2023-06-07 | Novaliq GmbH | 2-perfluorobutyl pentane for ophthalmic administration |
| US20170087100A1 (en) | 2015-09-30 | 2017-03-30 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| CN108883172A (zh) | 2015-11-18 | 2018-11-23 | 福迈康股份公司 | 包含vegf拮抗剂的液体配制品的预填充药物包装 |
| CN108778330A (zh) | 2016-01-08 | 2018-11-09 | 科尼尔赛德生物医学公司 | 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置 |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| AU2017329983B2 (en) | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| CN109803650A (zh) | 2016-09-28 | 2019-05-24 | 诺瓦利克有限责任公司 | 包含大麻素受体结合配体的组合物 |
| CN109937034B (zh) | 2016-11-21 | 2022-09-16 | 济世-伊沃泰克生物制品有限公司 | 阿柏西普制剂及其用途 |
| WO2018114557A1 (en) | 2016-12-22 | 2018-06-28 | Novaliq Gmbh | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| MX381639B (es) | 2016-12-23 | 2025-03-13 | Novaliq Gmbh | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| EP4065082A1 (en) | 2019-11-27 | 2022-10-05 | Novaliq GmbH | Suspension comprising a protein particle suspended in a non-aqueous vehicle |
-
2014
- 2014-07-23 DK DK14742509.4T patent/DK3024484T3/en active
- 2014-07-23 AU AU2014295052A patent/AU2014295052B2/en active Active
- 2014-07-23 BR BR112016001522-3A patent/BR112016001522B1/pt active IP Right Grant
- 2014-07-23 EP EP14742509.4A patent/EP3024484B1/en active Active
- 2014-07-23 US US14/907,254 patent/US10273298B2/en active Active
- 2014-07-23 JP JP2016528526A patent/JP6503349B2/ja active Active
- 2014-07-23 WO PCT/EP2014/065840 patent/WO2015011199A1/en not_active Ceased
- 2014-07-23 CN CN201480040002.1A patent/CN105555311B/zh active Active
- 2014-07-23 ES ES14742509.4T patent/ES2687094T3/es active Active
- 2014-07-23 PL PL14742509T patent/PL3024484T3/pl unknown
- 2014-07-23 PT PT14742509T patent/PT3024484T/pt unknown
- 2014-07-23 MX MX2016001018A patent/MX370207B/es active IP Right Grant
- 2014-07-23 CN CN202111078105.5A patent/CN114028560A/zh active Pending
- 2014-07-23 CA CA2918419A patent/CA2918419C/en active Active
- 2014-07-23 KR KR1020167001802A patent/KR102272568B1/ko active Active
-
2019
- 2019-03-06 US US16/294,506 patent/US20190256591A1/en not_active Abandoned
-
2021
- 2021-05-14 US US17/320,693 patent/US11987623B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210340248A1 (en) | 2021-11-04 |
| PL3024484T3 (pl) | 2018-11-30 |
| CA2918419C (en) | 2022-05-03 |
| AU2014295052A1 (en) | 2016-02-11 |
| EP3024484B1 (en) | 2018-06-20 |
| US10273298B2 (en) | 2019-04-30 |
| MX370207B (es) | 2019-12-05 |
| KR102272568B1 (ko) | 2021-07-05 |
| JP2016525139A (ja) | 2016-08-22 |
| KR20160034307A (ko) | 2016-03-29 |
| US20160159902A1 (en) | 2016-06-09 |
| CN114028560A (zh) | 2022-02-11 |
| CA2918419A1 (en) | 2015-01-29 |
| CN105555311A (zh) | 2016-05-04 |
| WO2015011199A1 (en) | 2015-01-29 |
| JP6503349B2 (ja) | 2019-04-17 |
| US20190256591A1 (en) | 2019-08-22 |
| DK3024484T3 (en) | 2018-10-08 |
| HK1224218A1 (zh) | 2017-08-18 |
| ES2687094T3 (es) | 2018-10-23 |
| AU2014295052B2 (en) | 2018-08-30 |
| US11987623B2 (en) | 2024-05-21 |
| MX2016001018A (es) | 2016-09-06 |
| CN105555311B (zh) | 2021-10-08 |
| EP3024484A1 (en) | 2016-06-01 |
| PT3024484T (pt) | 2018-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11987623B2 (en) | Stabilized antibody compositions | |
| EP3412310B1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP7089121B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| JP7475335B2 (ja) | Ｃｓｆ－１ｒ抗体製剤 | |
| CN109475597B (zh) | 眼用药物组合物 | |
| RU2679124C2 (ru) | Препарат для биспецифических активаторов т-клеток (bite) | |
| TWI820270B (zh) | 抗體配方 | |
| JP2017105754A (ja) | 低粘度抗体組成物 | |
| JP2025504063A (ja) | 安定抗体製剤 | |
| HK1224218B (en) | Stabilized antibody compositions | |
| EA042435B1 (ru) | Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B65X | Notification of requirement for priority examination of patent application | ||
| B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2014, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2014, OBSERVADAS AS CONDICOES LEGAIS |